1

FDA Nod for UX111 Marks Gene Therapy Milestone in MPS IIIA

 News Discuss 
In February 2025, Ultragenyx received FDA acceptance for its UX111 Biologics License Application targeting Sanfilippo Syndrome Type A . https://www.datamintelligence.com/research-report/mucopolysaccharidoses-market

Comments

    No HTML

    HTML is disabled


    Report Page

Who Upvoted this Story

Search

Published News